Pharmacokinetics of orally administered pirfenidone in male and female beagles
- 20 October 2004
- journal article
- clinical trial
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 27 (5) , 361-367
- https://doi.org/10.1111/j.1365-2885.2004.00612.x
Abstract
Pirfenidone, a promising antifibrotic agent, was administered orally to dogs at 0, 40, 140, and 400 mg/kg/day. Serum was collected for pirfenidone assay at 0, 26 and 39 weeks of treatment. From the pirfenidone concentrations, pharmacokinetic parameters were determined for each dog at each treatment interval. The only significant differences because of gender were for concentration maxima. Unsurprisingly, there were many significant differences because of dose in concentration maximum and area under curve (AUC), and significant, positive linear correlations of both parameters with dose. There were few significant differences in time of maximal concentration and no correlation with dose. The mean +/- SE clearances were 1.99 +/- 0.13, 1.64 +/- 0.13 and 1.78 +/- 0.14 L/h/kg for doses of 40, 140, and 400 mg/kg, respectively, with no significant differences attributable to dose. There was an unexplained pattern in maximal concentration and AUC with regard to duration of treatment, with the parameters being highest at week 0, lowest at week 26, and intermediate at week 39. Clearance had the reverse pattern; time of maximal concentration had no pattern.Keywords
This publication has 14 references indexed in Scilit:
- Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administrationBiopharmaceutics & Drug Disposition, 2002
- Pirfenidone for chronic progressive multiple sclerosisMultiple Sclerosis Journal, 2001
- Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin‐diabetic ratsBritish Journal of Pharmacology, 2001
- Treatment of Idiopathic Pulmonary Fibrosis with a New Antifibrotic Agent, PirfenidoneAmerican Journal of Respiratory and Critical Care Medicine, 1999
- Lung Fibrosis is Ameliorated by Pirfenidone Fed in Diet After the Second Dose In A Three-Dose Bleomycin-Hamster ModelExperimental Lung Research, 1998
- A Comparative Computer Simulation Study of Three Different Sparse-Sampling Methods for the Estimation of Steady-State Area Under the Concentration—time Curve (AUC) and Maximum concentration (Cmax) in ToxicokineticsJournal of Pharmaceutical Sciences, 1997
- Pharmacokinetics of an antifibrotic agent, pirfenidone, in haemodialysis patientsEuropean Journal of Clinical Pharmacology, 1997
- Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in miceToxicology Letters, 1997
- Prediction of Furan Pharmacokinetics from Hepatocyte Studies: Comparison of Bioactivation and Hepatic Dosimetry in Rats, Mice, and HumansToxicology and Applied Pharmacology, 1996
- Interspecies Pharmacokinetic Scaling and the Evolutionary-Comparative ParadigmDrug Metabolism Reviews, 1984